UTHR UNITED THERAPEUTICS Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: UTHR

Price (delayed)

$239.98

Market cap

$11.28B

P/E Ratio

12.45

Dividend/share

N/A

EPS

$19.28

Enterprise value

$10.97B

United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and ...

Highlights
UNITED THERAPEUTICS's net income has increased by 27% YoY and by 3.2% QoQ
The equity has increased by 25% year-on-year and by 6% since the previous quarter
The quick ratio has dropped by 53% year-on-year and by 47% since the previous quarter
The gross margin has declined by 4.6% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.unither.com/
Peers: LLY GILD TEVA PFE

Key stats

What are the main financial stats of UTHR
Market
Shares outstanding
46.99M
Market cap
$11.28B
Enterprise value
$10.97B
Valuations
Price to earnings (P/E)
12.45
Price to book (P/B)
1.97
Price to sales (P/S)
5.11
EV/EBIT
9.03
EV/EBITDA
8.66
EV/Sales
4.98
Earnings
Revenue
$2.2B
EBIT
$1.21B
EBITDA
$1.27B
Free cash flow
$764.3M
Per share
EPS
$19.28
Free cash flow per share
$16.3
Book value per share
$121.71
Revenue per share
$47
TBVPS
$148.81
Balance sheet
Total assets
$7.02B
Total liabilities
$1.31B
Debt
$800M
Equity
$5.71B
Working capital
$2.71B
Liquidity
Debt to equity
0.14
Current ratio
4.65
Quick ratio
4.21
Net debt/EBITDA
-0.24
Margins
EBITDA margin
57.5%
Gross margin
88.9%
Net margin
40.8%
Operating margin
49.9%
Efficiency
Return on assets
13.8%
Return on equity
17.1%
Return on invested capital
21.1%
Return on capital employed
19.3%
Return on sales
55.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

UTHR stock price

How has the UNITED THERAPEUTICS stock price performed over time
Intraday
-0.14%
1 week
3.41%
1 month
5.17%
1 year
-13.24%
YTD
-13.7%
QTD
6.25%

Financial performance

How have UNITED THERAPEUTICS's revenue and profit performed over time
Revenue
$2.2B
Gross profit
$1.96B
Operating income
$1.1B
Net income
$899.8M
Gross margin
88.9%
Net margin
40.8%
UNITED THERAPEUTICS's net income has increased by 27% YoY and by 3.2% QoQ
The company's revenue rose by 19% YoY and by 4.4% QoQ
The company's gross profit rose by 13% YoY and by 3.2% QoQ
The operating income has grown by 13% YoY

Growth

What is UNITED THERAPEUTICS's growth rate over time

Valuation

What is UNITED THERAPEUTICS stock price valuation
UTHR P/E details
P/E
12.45
P/B
1.97
P/S
5.11
EV/EBIT
9.03
EV/EBITDA
8.66
EV/Sales
4.98
The company's EPS rose by 24% YoY and by 2.4% QoQ
The stock's P/E is 10% below its 5-year quarterly average of 13.8 and 9% below its last 4 quarters average of 13.7
The equity has increased by 25% year-on-year and by 6% since the previous quarter
UTHR's price to book (P/B) is 6% lower than its last 4 quarters average of 2.1 but 3.7% higher than its 5-year quarterly average of 1.9
The stock's P/S is 19% above its 5-year quarterly average of 4.3 but 5% below its last 4 quarters average of 5.4
The company's revenue rose by 19% YoY and by 4.4% QoQ

Efficiency

How efficient is UNITED THERAPEUTICS business performance
The ROIC has grown by 13% YoY
The company's return on sales rose by 9% YoY
UNITED THERAPEUTICS's return on assets has increased by 7% YoY
The ROE has grown by 3% YoY but it has contracted by 2.3% from the previous quarter

Dividends

What is UTHR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for UTHR.

Financial health

How did UNITED THERAPEUTICS financials performed over time
The quick ratio has dropped by 53% year-on-year and by 47% since the previous quarter
The current ratio has plunged by 52% YoY and by 46% from the previous quarter
The debt is 86% less than the equity
The equity has increased by 25% year-on-year and by 6% since the previous quarter
UNITED THERAPEUTICS's debt to equity has decreased by 22% YoY and by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.